For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-09-30 | ||
|---|---|---|---|---|
| Research and development | 2,587 | 2,361 | ||
| General and administrative | 1,600 | 2,687 | ||
| Total operating expense | 4,187 | 5,048 | ||
| Loss from operations | -4,187 | -5,048 | ||
| Interest expense-Nonrelated Party | 33 | 31 | ||
| Interest expense-Related Party | 5 | 10 | ||
| Change in fair value of other liabilities and derivatives-Nonrelated Party | -45 | 93 | ||
| Change in fair value of other liabilities and derivatives-Related Party | -3 | 7 | ||
| Other income (expense), net | 73 | 18 | ||
| Total other income, net | 83 | -123 | ||
| Loss before income taxes | -4,104 | -5,171 | ||
| Income tax provision | 4 | 10 | ||
| Net loss | -4,108 | -5,181 | ||
| Net loss attributable to noncontrolling interest | - | -32 | ||
| Net loss attributable to controlling interest | -4,108 | -5,149 | ||
| Deemed dividend on warrants | -309 | -5,673 | ||
| Net loss attributable to common stockholders | -4,417 | -10,822 | ||
| Basic EPS | -0.43 | -2.21 | ||
| Diluted EPS | -0.43 | -2.21 | ||
| Basic Average Shares | 10,308,000 | 4,907 | ||
| Diluted Average Shares | 10,308,000 | 4,907 | ||
Calidi Biotherapeutics, Inc. (CLDI)
Calidi Biotherapeutics, Inc. (CLDI)